Kirby R S
Department of Urology, St George's Hospital, London.
Int J Clin Pract. 1998 Sep;52(6):402-7.
This review analyses the expanding role of alpha adrenoceptor blockers in the treatment of BPH and examines the rationale for their use. The safety and efficacy of currently available alpha adrenoceptor blockers is reviewed, with emphasis on the most extensively studied agent, doxazosin. Like other alpha adrenoceptor blockers, doxazosin improves both symptoms of BPH and urinary flow rates by a statistically significant effect compared with placebo. Doxazosin also significantly reduces blood pressure in the 30% of BPH sufferers who also have hypertension; furthermore, there is a beneficial effect on lipid metabolism, which may translate into a reduced risk of coronary heart disease. It is concluded that existing alpha adrenoceptor blockers constitute a valuable adjunct to other BPH therapies, and further refinement of alpha adrenoceptor selectivity based on the alpha-1A subtype in the near future promises even better targeted alpha blockade.
本综述分析了α肾上腺素能受体阻滞剂在良性前列腺增生症（BPH）治疗中不断扩大的作用，并探讨了其用药原理。对目前可用的α肾上腺素能受体阻滞剂的安全性和有效性进行了综述，重点关注研究最为广泛的药物多沙唑嗪。与其他α肾上腺素能受体阻滞剂一样，与安慰剂相比，多沙唑嗪通过具有统计学意义的效应改善了BPH的症状和尿流率。多沙唑嗪还使30%同时患有高血压的BPH患者的血压显著降低；此外，对脂质代谢有有益作用，这可能转化为降低冠心病风险。得出的结论是，现有的α肾上腺素能受体阻滞剂是其他BPH治疗方法的有价值辅助药物，在不久的将来基于α-1A亚型进一步优化α肾上腺素能受体选择性有望实现更有针对性的α受体阻滞。
